dilTIAZem Injectable Bags Recalled Nationwide for Sterility Concerns
Central Admixture Pharmacy Services is recalling 1,230 bags of dilTIAZem injectable due to lack of sterility assurance following FDA inspection. Affected lots were distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA classified this as Class II. The source reports no illnesses or injuries from the recalled product. As a risk-of-harm product where injury has not yet been reported, this meets the rubric criterion for severity score 3.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling dilTIAZem added to dextrose 5% (125 mg/125 mL per bag). The recall involves 1,230 bags distributed nationwide.
The recall affects Lot #37-896365, 37-896367, 37-896370 (expiring 05/31/2023) and Lot #37-896857, 37-896858, 37-896859 (expiring 06/02/2023), identified by NDC 72185-6054-1.
An FDA inspection raised concerns about the lack of assurance of sterility for these products. Sterility is a requirement for intravenous medications.
Anyone who received these lots should stop using the product immediately and contact Central Admixture Pharmacy Services, Inc. for further instructions or disposal guidance.
The recalled product
- Product
- dilTIAZem added to dextrose 5%, 125 mg/125 mL* (1 mg/mL), 125 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 72185-6054-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable
- Hazard
- lack-of-sterility
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot # 37-896365
- 37-896367
- 37-896370
- Exp 05/31/2023
- 37-896857
- 37-896858
- 37-896859
- Exp 06/02/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27